belapectin + Placebo
Phase 2/3Terminated 0 watching 0 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prevention of Esophageal Varices
Conditions
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
Trial Timeline
Jun 25, 2020 → Apr 10, 2025
NCT ID
NCT04365868About belapectin + Placebo
belapectin + Placebo is a phase 2/3 stage product being developed by Galectin Therapeutics for Prevention of Esophageal Varices. The current trial status is terminated. This product is registered under clinical trial identifier NCT04365868. Target conditions include Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04365868 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Prevention of Esophageal Varices
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| edoxaban + enoxaparin sodium | Daiichi Sankyo | Phase 3 | 77 |
| Mifepristone | Eli Lilly | Phase 2 | 52 |
| EXANTA | AstraZeneca | Phase 2 | 52 |
| Risk of low dose aspirin discontinuation | AstraZeneca | Pre-clinical | 23 |
| DAPA/MET XR + DAPA + MET XR | AstraZeneca | Phase 3 | 77 |
| Esomeprazole + Placebo | AstraZeneca | Phase 3 | 77 |
| PCV15 | Merck | Pre-clinical | 23 |
| Raltegravir | Merck | Approved | 85 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 77 |
| V501 | Merck | Phase 3 | 77 |
| Zostavax | Merck | Phase 3 | 77 |
| V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 | Merck | Phase 3 | 77 |
| Letermovir + Placebo | Merck | Phase 3 | 77 |
| Meningococcal C conjugate vaccine | Novartis | Approved | 85 |
| Enteric-coated mycophenolate sodium | Novartis | Phase 3 | 77 |
| Meningococcal C conjugate vaccine | Novartis | Approved | 85 |
| rMenB+OMV NZ | Novartis | Phase 3 | 77 |
| Enteric-Coated Mycophenolate Sodium | Novartis | Phase 3 | 77 |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml | Novartis | Phase 3 | 77 |
| Meningococcal C Conjugate Vaccine | Novartis | Phase 3 | 77 |